The Merck oncology pipeline will present first-time Phase 3 results for intismeran autogene plus KEYTRUDA, sacituzumab tirumotecan and KEYTRUDA monotherapy in Madrid from Oct. 23-27, 2026, alongside more than 90 additional abstracts.
New post-hoc analyses from Eli Lilly show Lilly Omvoh (mirikizumab-mrkz) helped 27.7% of ulcerative colitis patients reach comprehensive disease control and 20.4% of Crohn’s disease patients reach corticosteroid-free deep remission at one year, including patients with prior biologic failure.
Charles River Laboratories and Magellan Stem Cells announced a collaboration on Oct. 13, 2026, bringing cGMP next-generation sequencing viral safety testing to Zelestrocel, Magellan’s off-the-shelf osteoarthritis stem cell therapy candidate.
Johnson & Johnson ICOTYDE (icotrokinra) reported two-year Phase 3 ICONIC-LEAD results at Fall Clinical Dermatology 2026. At Week 112, ≥72% of treated adults and adolescents with plaque psoriasis achieved PASI 90, with no new safety signals identified.
The FDA has approved Tecentriq and Tecentriq Hybreza with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III dMMR colon cancer, based on the phase III ATOMIC trial.
The FDA has approved Tecentriq and Tecentriq Hybreza with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III dMMR colon cancer, based on the phase III ATOMIC trial.
The Novartis Rhapsido FDA approval makes remibrutinib the first approved treatment for adults with symptomatic dermographism not controlled by H1 antihistamines. It builds on Rhapsido’s existing chronic spontaneous urticaria indication.
ViiV Healthcare Cabenuva (cabotegravir + rilpivirine) met the primary endpoint of the phase IIIb CROWN study, with superior six-month viral suppression versus standard oral ART in people with detectable HIV. The use is investigational and not approved.
AbbVie and Genmab report that Epcoritamab R-CHOP reduced the risk of progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma, in the Phase 3 EPCORE DLBCL-2 trial. The combination remains investigational.
The Roche fenebrutinib FDA filing has been accepted under priority review for relapsing and primary progressive multiple sclerosis. The application draws on the FENhance 1, FENhance 2 and FENtrepid Phase III studies.
